Cancer drug bonanza

Treatments for advanced cancers of the lung and cervix and advanced melanoma are included in the latest TGA and PBS listings, along with a new approach for the rare blood cancer myelofibrosis.

The TGA has approved bevacizumab for advanced cervical cancer, after a clinical trial showed it prolonged survival by a median of 3.7 months in the difficult-to-treat condition.

It is the first biologic agent to be approved for treatment of persistent, recurrent or metastatic carcinoma of the cervix, and is now licensed to be used in Australia in conjunction with the standard chemotherapy agents paclitaxel and cisplatin